Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

This study is only for people who have already been part of two specific earlier studies (called 417-201-00007 or VIS649-201) involving the same medicine, sibeprenlimab. To be considered, you must have completed most of the doses in those previous studies and had your final study visit without any major safety concerns. Importantly, your doctor must also believe that continuing to take sibeprenlimab could still be helpful for your IgA Nephropathy.

You also need to be able to understand what joining the study involves and be willing to give your written permission. It's important that you can reliably attend all appointments and follow the study instructions. The study is open to adults aged 18 and over.

You would not be able to join if you didn't finish one of the previous studies, or if you had serious side effects during those studies that your doctor thought were due to the medicine. Also, if you regularly didn't follow the rules of the previous studies, you wouldn't be eligible. Pregnant women or those who could become pregnant, or their partners, must agree to use effective contraception during the study and for a period afterwards.

If you join this study, you would continue to receive the study medication, sibeprenlimab. This medicine is given as an injection under the skin every four weeks.

The study aims to look at the long-term effects, so it will involve regular visits to the clinic for assessments. These visits will help doctors check your general health, how your kidneys are doing, and if you are experiencing any side effects. You'll have blood tests, urine tests, and possibly other checks to monitor your condition and the effects of the treatment. The total length of your participation would depend on the study design and your individual circumstances, but the aim is long-term follow-up.